Diversify Wealth Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 68.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 19,691 shares of the company’s stock after purchasing an additional 7,982 shares during the period. Diversify Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,797,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the stock. International Assets Investment Management LLC lifted its holdings in Johnson & Johnson by 20,130.0% during the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock worth $559,832,000 after buying an additional 3,437,397 shares during the last quarter. Marshall Wace LLP raised its position in shares of Johnson & Johnson by 506.9% during the 2nd quarter. Marshall Wace LLP now owns 3,884,962 shares of the company’s stock valued at $567,826,000 after acquiring an additional 3,244,862 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after purchasing an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after purchasing an additional 1,729,281 shares during the period. Finally, Holocene Advisors LP acquired a new stake in shares of Johnson & Johnson during the third quarter worth $225,040,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Stock Up 0.7 %
JNJ stock opened at $148.10 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $356.57 billion, a PE ratio of 21.43, a P/E/G ratio of 2.39 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a 50 day simple moving average of $148.35 and a 200 day simple moving average of $156.11.
Johnson & Johnson Dividend Announcement
Analyst Upgrades and Downgrades
Several research firms have recently commented on JNJ. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Bank of America cut their price objective on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research report on Friday, January 17th. Finally, Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Eight equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $173.27.
Read Our Latest Report on Johnson & Johnson
Insider Transactions at Johnson & Johnson
In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
- Five stocks we like better than Johnson & Johnson
- There Are Different Types of Stock To Invest In
- SAP’s Strong Momentum: A Bullish Setup for Investors
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- What is the Dow Jones Industrial Average (DJIA)?
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.